唐氏综合征患者中实体瘤和血液系统恶性肿瘤的发病率：系统回顾和荟萃分析。

IF 5.5 2区医学 Q1 HEMATOLOGY

Critical reviews in oncology/hematology Pub Date : 2024-11-15 DOI:10.1016/j.critrevonc.2024.104558

Nayara Rozalem Moretti , Ana Beatriz Nardelli da Silva , Letícia Vieira Guimarães , Ian de Paula Bezerra , João Arthur Cerqueira Taumaturgo , Natália Gabrielli Silva Alves , Francinny Alves Kelly , Francisco Cezar Aquino de Moraes

{"title":"唐氏综合征患者中实体瘤和血液系统恶性肿瘤的发病率：系统回顾和荟萃分析。","authors":"Nayara Rozalem Moretti , Ana Beatriz Nardelli da Silva , Letícia Vieira Guimarães , Ian de Paula Bezerra , João Arthur Cerqueira Taumaturgo , Natália Gabrielli Silva Alves , Francinny Alves Kelly , Francisco Cezar Aquino de Moraes","doi":"10.1016/j.critrevonc.2024.104558","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Patients with Down syndrome (DS) have a unique genetic and clinical profile that may increase the risk of cancer.</div></div><div><h3>Methods</h3><div>A literature search on PubMed, Scopus, Web of Science, and the Cochrane databases was conducted, focusing on studies to investigate the prevalence of solid and hematologic tumors in DS.</div></div><div><h3>Results</h3><div>Fifteen studies were included, encompassing 62,121 individuals with Down syndrome (DS). The overall prevalence of cancer in DS was 2.02 % (95 % CI: 1.63–2.50 %). The analysis of hematological tumors revealed a prevalence of 1.18 % (95 % CI: 0.86 % - 1.62 %) for leukemia, 0.86 % (95 % CI: 0.73 % - 1.01 %) for acute lymphoblastic leukemia, and 0.51 % (95 % CI: 0.29 % - 0.90 %) for acute myeloid leukemia. Among solid tumors, testicular cancer had the highest prevalence, at 0.22 % (95 % CI: 0.12 % - 0.43 %).</div></div><div><h3>Conclusions</h3><div>Our results highlight the need for targeted screening strategies, prevention strategies and treatment protocols among those with Down syndrome.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"205 ","pages":"Article 104558"},"PeriodicalIF":5.5000,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The prevalence of solid tumors and hematologic malignancies among patients with Down syndrome: A systematic review and meta-analysis\",\"authors\":\"Nayara Rozalem Moretti , Ana Beatriz Nardelli da Silva , Letícia Vieira Guimarães , Ian de Paula Bezerra , João Arthur Cerqueira Taumaturgo , Natália Gabrielli Silva Alves , Francinny Alves Kelly , Francisco Cezar Aquino de Moraes\",\"doi\":\"10.1016/j.critrevonc.2024.104558\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Patients with Down syndrome (DS) have a unique genetic and clinical profile that may increase the risk of cancer.</div></div><div><h3>Methods</h3><div>A literature search on PubMed, Scopus, Web of Science, and the Cochrane databases was conducted, focusing on studies to investigate the prevalence of solid and hematologic tumors in DS.</div></div><div><h3>Results</h3><div>Fifteen studies were included, encompassing 62,121 individuals with Down syndrome (DS). The overall prevalence of cancer in DS was 2.02 % (95 % CI: 1.63–2.50 %). The analysis of hematological tumors revealed a prevalence of 1.18 % (95 % CI: 0.86 % - 1.62 %) for leukemia, 0.86 % (95 % CI: 0.73 % - 1.01 %) for acute lymphoblastic leukemia, and 0.51 % (95 % CI: 0.29 % - 0.90 %) for acute myeloid leukemia. Among solid tumors, testicular cancer had the highest prevalence, at 0.22 % (95 % CI: 0.12 % - 0.43 %).</div></div><div><h3>Conclusions</h3><div>Our results highlight the need for targeted screening strategies, prevention strategies and treatment protocols among those with Down syndrome.</div></div>\",\"PeriodicalId\":11358,\"journal\":{\"name\":\"Critical reviews in oncology/hematology\",\"volume\":\"205 \",\"pages\":\"Article 104558\"},\"PeriodicalIF\":5.5000,\"publicationDate\":\"2024-11-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Critical reviews in oncology/hematology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1040842824003019\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical reviews in oncology/hematology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1040842824003019","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景：唐氏综合征（DS）患者具有独特的遗传和临床特征，可能会增加患癌症的风险：方法：在 PubMed、Scopus、Web of Science 和 Cochrane 数据库中进行文献检索，重点研究唐氏综合征患者实体瘤和血液肿瘤的患病率：结果：共纳入 15 项研究，涉及 62121 名唐氏综合征（DS）患者。唐氏综合征患者的癌症总发病率为 2.02%（95% CI：1.63% 至 2.50%）。对血液肿瘤的分析显示，白血病的患病率为 1.18%（95% CI：0.86% - 1.62%），急性淋巴细胞白血病为 0.86%（95% CI：0.73% - 1.01%），急性髓性白血病为 0.51%（95% CI：0.29% - 0.90%）。在实体瘤中，睾丸癌的发病率最高，为 0.22%（95% CI：0.12% - 0.43%）：我们的研究结果表明，有必要在唐氏综合征患者中开展有针对性的筛查策略、预防策略和治疗方案。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The prevalence of solid tumors and hematologic malignancies among patients with Down syndrome: A systematic review and meta-analysis

Background

Patients with Down syndrome (DS) have a unique genetic and clinical profile that may increase the risk of cancer.

Methods

A literature search on PubMed, Scopus, Web of Science, and the Cochrane databases was conducted, focusing on studies to investigate the prevalence of solid and hematologic tumors in DS.

Results

Fifteen studies were included, encompassing 62,121 individuals with Down syndrome (DS). The overall prevalence of cancer in DS was 2.02 % (95 % CI: 1.63–2.50 %). The analysis of hematological tumors revealed a prevalence of 1.18 % (95 % CI: 0.86 % - 1.62 %) for leukemia, 0.86 % (95 % CI: 0.73 % - 1.01 %) for acute lymphoblastic leukemia, and 0.51 % (95 % CI: 0.29 % - 0.90 %) for acute myeloid leukemia. Among solid tumors, testicular cancer had the highest prevalence, at 0.22 % (95 % CI: 0.12 % - 0.43 %).

Conclusions

Our results highlight the need for targeted screening strategies, prevention strategies and treatment protocols among those with Down syndrome.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Critical reviews in oncology/hematology 医学-血液学

CiteScore

11.00

自引率

3.20%

发文量

213

审稿时长

55 days

期刊介绍： Critical Reviews in Oncology/Hematology publishes scholarly, critical reviews in all fields of oncology and hematology written by experts from around the world. Critical Reviews in Oncology/Hematology is the Official Journal of the European School of Oncology (ESO) and the International Society of Liquid Biopsy.